Summary In the search for effective chemotherapy regimens which can be used in multimodality treatment programmes for patients with cancer of the oesophagus, we conducted a phase II trial to determine the activity and toxicity of the combination of cisplatin and etoposide in patients with advanced squamous cell carcinoma of the oesophagus. Seventy-three consecutive patients with unresectable or metastatic squamous cell carcinoma of the thoracic oesophagus were treated with cisplatin 80 mg m-2 by 4 h infusion on day 1, etoposide 100 mg (fixed dose) by 2 h infusion on day 1 and 2, and etoposide 200 mg m-2 orally on day 3 and 5. Courses were repeated every 4 weeks, for a maximum of six courses. The oral dosages of etoposide were modified individually until a significant degree of myelosuppression was reached. Of 65 evaluable patients, five complete responses (CRs) and 26 partial responses (PRs) were seen, for an overall response rate of 48% (95% confidence interval 35-60%). Median time to progression was 7 months (range 3-72+months). There were two toxic deaths (neutropenic sepsis). The response rate equals that of other cisplatin-based regimens. Its toxicity profile allows addition of a third active drug such as 5-fluorouracil.
incidence ratio in the Netherlands is 1.07 for males and 0.99 for females, with an incidence of approximately 900 in 1990 and a male/female ratio of 2.5 (Visser et al., 1990) . Most patients are in their fifth to seventh decade of life. A longstanding history of cigarette abuse and heavy alcohol intake is strongly associated with the development of oesophageal cancer, in particular with oesophageal squamous cell carcinoma (ESCC) . Although approximately half of the patients present with localised disease, many of them will have recurrences of metastatic disease despite aggressive local treatment; the 5-year survival rate after radical resection is only 10 -15% (Muller et al., 1990) . Obviously, there is a need for effective systemic treatment. In reviews on single-agent activity with cisplatin, 5-FU, bleomycin and mitomycin, the response rate appears to be 15-20%, with a short duration of response (3 months) (Roth et al., 1993) . Etoposide showed promising activity in ESCC in a phase I study, although a phase II study with a low-dose schedule in pretreated patients could not confirm these early results (Radice et al., 1979; Coonley et al., 1983) . However, with a higher dose in non-pretreated metastatic patients, considerable activity was documented (Harstrick et al., 1992) . Based on these data and our previously reported experience that the combination of cisplatin and etoposide is safe and effective in non-small-cell lung cancer (Splinter et al., 1986) , we have performed a phase II study with the combination of these two drugs in patients with advanced and/or metastatic squamous cell carcinoma of the oesophagus.
Patients and methods

Patient selection
All patients who entered the study were 
Treatment
The intravenous (i.v.) treatment consisted of prehydration with 1500 ml of saline/glucose (0.45%/2.5%) and 4 g of magnesium sulphate over 14 h, followed by 100 mg (fixed dose) etoposide dissolved in 500 ml 0.9% saline given over 2 h (day 1). Cisplatin (80 mg m-2) dissolved in 1000 ml 0.9% saline was then administered over 4 h, followed by posthydration with 3500 ml saline/glucose over 24 h. During this post-hydration period another 100 mg (fixed dose) of etoposide dissolved in 500 ml 0.9% saline was given over 2 h, 24 h after the first dose of etoposide (day 2). Table I . At the time of diagnosis, 60 patients had metastatic disease with the primary tumour in situ, and three patients had non-resectable primary tumours only. Ten patients had developed distant metastases at a median time of 10.5 months (range 3-81 months) after local treatment [oesophageal resection (n=3), radiotherapy alone (n=2), radiotherapy followed by oesophageal resection (n=5)]. Two patients were not evaluable for response and toxicity because of treatment refusal and loss to follow-up after the first course for other than tumouror treatment-related reasons. Six patients were not evaluable for response because of tumour-related complications [lethal haematemesis in the presence of normal WBC and platelets after the first course (n = 1), formation of fistulas between the primary tumour and trachea and pleura respectively after the first course with no change of disease (n = 2), toxic death, i.e. neutropenic sepsis before the first response evaluation (n = 2), or WHO grade 3 neurotoxicity after the first course (n= 1)]. Therefore, 71 patients were evaluable for toxicity and 65 patients for response. The median survival time in all patients (n = 73) from the start of treatment was 8.5 months (range 0.5-72+months). Nineteen patients (26%) survived for more than 1 year. The median survival time in responding patients without consolidation treatment (radiotherapy, surgery) was 10 months (range 3.0-72+months), compared with a median of 5.5 months (range 1.0-26.4 months) in non-responding patients.
Response
Discussion
Notwithstanding a substantial decrease in post-operative mortality after oesophageal resection in the last 15 years, long-term survival rates in patients with oesophageal cancer are still very low as a consequence of the systemic nature of this disease. As a result of the relative rarity and the poor performance status of most patients, data on systemic treatment in oesophageal cancer are scarce. No controlled trials of chemotherapy vs best supportive care have been reported.
Cisplatin as a single agent in ESCC was reported for the first time in 1980 (Davis et al., 1980; Ravry et al., 1985; Engstrom et al., 1983) . The Southwest Oncology Group (SWOG) reported an overall response rate of 26% among 35 evaluable patients (6 PRs and 3 CRs) with a regimen of 50 mg m-2 cisplatin on day 1 and 8 (Panetierre et al., 1984) . The median response duration in these trials was 3-4 months. Despite the limited value of compiled trial data, an overall response rate of 25% with single-agent cisplatin in (Ajani. 1994) . The doselimiting toxicity is neurotoxicity (especially in patients with high alcohol intake) and ototoxicity.
Because of encouraging results of etoposide in patients with ESCC in phase I studies, Harstrick et al. (1992) Steel et al.. 1988; Mannell. 1989; Cappelaere et al.. 1993) . Preliminary results from a phase II trial with paclitaxel have shown interesting activity: an overall response rate of 31% (95% CI 17-45%, no CR) with a median response duration of 4 months (range 1-11 + months) was recorded . In the clinic. cisplatin appears to be an excellent drug for combination chemotherapy, especially with etoposide or teniposide.
because of few overlapping toxicities. In addition, dosedependent activity and even synergy has been demonstrated in animal models (Achterrath et al.. 1982; Chen et al.. 1984; Ross et al.. 1984 : Long et al.. 1985 .
Until now, more than 15 combination schemes for oesophageal cancer have been reported. Two schedules have been studied with adequate numbers of patients: cisplatin and 5-fluorouracil and cisplatin with vindesine and bleomycin. This latter combination has induced substantial pulmonary toxicity. although a response rate of approximately 50% in several studies was reported (Kelsen et al.. 1983 : Dinwoodie et al.. 1986 . Response rates of cisplatin with 5-fluorouracil and or leucovonrn treatment are in the 35-50% range. sometimes even higher (Bleiberg et al.. 1991 : De Besi et al., 1986 Iizuka et al.. 1991 : Hayashi et al.. 1992 : Spielmann et al., 1993 .
In this study. we applied the same dosages and schedule of cisplatim and etoposide. as we have previously reported in patients with non-small-cell lung cancer (Splinter et al.. 1986 ). The rationale of an extended administration of etoposide over several days has been justified by several authors in the light of the schedule-dependent cytotoxicity of this drug (Cavalli et al., 1978; Slevin et al.. 1989 ). In addition, this regimen reduces the length of hospital stay to a maximum of 3 days. The toxicity turned out to be manageable w-tih two toxic deaths (3%) and seven other patients (10%) who refused continuation because of side-effects. Dose escalations of etoposide could be applied more often than dose reductions were required. The dominant side-effects of nausea and vomiting (WHO grade 2 and 3. 72%) observed in our study, can presently be reduced or even eliminated using 5-HT3 receptor antagonists.
Adenocarcinoma of the oesophagus is being seen increasingly frequently among Western European and American patients. In our hands however. this regimen showed no activity in patients with this histological subtype. as previously reported (Kok et al.. 1988) .
Our results seem to equal those of other cisplatin-based regimens. The favourable toxicity profile of our regimen has led us to perform a phase II trial of the combination of cisplatin. etoposide and a third active drug. 5-fluorouracil.
